Novo's Wegovy pill hit 721K Q1 prescriptions ahead of May 6 print, Drexel Q&A on peptide safety, Nature GLP-1 umbrella review, Pfizer Q1 + 20 obesity trials.
Read digest →Foundayo single liver FAERS case rocks LLY before Lilly + RBC defend, Biomea T1D C-peptide data, Immutep eftilagimod to ASCO, CordenPharma Boulder $500M.
Read digest →Novo retires Rybelsus brand for Ozempic Pill, Manchester Nature Comms penicillin biosynthesis, Ozempic Face data, Roche ENITH Phase 3, Wegovy pill hits 113K scripts.
Read digest →Lilly retatrutide TRANSCEND T2D1 reads out, Amgen MariTide Phase 3 detail at Q1, Mount Sinai liver-detargeted mRNA cancer vaccines, BioVaxys MVP-S to ASCO 2026.
Read digest →Novo unveils Ozempic pill for US adults with T2D plus WW Med+ and GoodRx channels, Lilly stock jumps 6.11% post-Q1, Foundayo Week 3 hits 5,612 scripts, Utah's PapB enzyme cyclizes GLP-1-like peptides.
Read digest →Lilly Q1 revenue jumps 56% as Mounjaro and Zepbound surge, FDA proposes 503B compounding ban for GLP-1s, UTHealth's BLMP6 hits fibulin-4 in metastatic TNBC, and Crinetics wins EU acromegaly approval.
Read digest →Zealand/Roche advance petrelintide to Phase 3; STAT warns RFK peptide push could unleash risky drugs; Rein LTI-03 IPF Phase 2 update; FDA pilots real-time trial monitoring.
Read digest →Boehringer/Zealand Survodutide SYNCHRONIZE-1 hits 16.6% weight loss at 76 weeks; BI 3034701 triple agonist heads to Phase 2; Boston peptide summit opens; Nature peptide papers.
Read digest →Eli Lilly Q1 earnings April 30; C&EN dives into amylin's GLP-1 challenge; AJSM peptide primer for sports medicine; trevogrumab and apitegromab muscle-preservation race.
Read digest →Pre-earnings week ahead — Lilly Apr 30, Novo May 6; Survodutide Phase 3 H1 readout; patient-access analyses post-FDA peptide announcement; AI-designed peptide tooling.
Read digest →Hims expands Lilly partnership and gets JPMorgan Buy at $35; Crinetics SSTR2 NDC; Cerapedics P-15 peptide bone graft Vizient deal; ABC affiliates warn on unregulated peptides.
Read digest →Novo's PIONEER TEENS pediatric T2D oral semaglutide positive; Fractyl REMAIN-1 gut-reset prevents post-GLP-1 weight regain; Roche projects $9B obesity pipeline peak sales.
Read digest →Trump admin extends Medicare GLP-1 Bridge through 2027 with taxpayer dollars after BALANCE collapse; MBX previews three once-monthly peptide candidates; AACR wraps.
Read digest →Trump cancels Medicare GLP-1 pilot after CVS pullout, BPC-157/TB-500 formally exit FDA Cat 2, Avacta PDC shows 3x Enhertu selectivity, 12M lost Wegovy coverage.
Read digest →Amazon enters GLP-1 at $25/mo, Kailera's $625M IPO is biotech's biggest since 2023, Perspective's alpha-PRRT hits 43% ORR, and Sapience's peptide antagonist debuts.
Read digest →Tirzepatide beats semaglutide 21.6% vs 15.4% in SURMOUNT-5, Bicycle PDC hits 40% ORR, 69/74 medspas still sell compounded GLP-1s, AACR peptide vaccines advance.
Read digest →Circle Pharma's CID-078 macrocyclic peptide debuts at AACR clinical plenary; Bicycle's BT5528 HNSCC data; Fedora's FPI-2119 bactericidal profile at ESCMID; HMD-AMP AI finds 37M+ AMPs.
Read digest →GLP-1 pioneers DiMarchi/Tschöp propose non-GLP-1 obesity approach; ESCMID Global opens in Munich; Circle Pharma macrocyclic peptide data at AACR; Scientific American on the peptide craze.
Read digest →